{"id":"noscapine","rwe":[{"pmid":"41717434","year":"2026","title":"In silico evaluation of natural opioid ligands interaction and their therapeutic prospects in neuroinflammation.","finding":"","journal":"In silico pharmacology","studyType":"Clinical Study"},{"pmid":"41686195","year":"2026","title":"Fabrication of Bortezomib and Noscapine-loaded PLGA nanoparticles: investigation of anti-bacterial, anti-proliferative activity, and apoptosis induction in triple-negative breast cancer cells.","finding":"","journal":"Naunyn-Schmiedeberg's archives of pharmacology","studyType":"Clinical Study"},{"pmid":"41663458","year":"2026","title":"Phenotypic classification of opium poppy genotypes (Papaver somniferum L.) based on morpho-phenological traits.","finding":"","journal":"Scientific reports","studyType":"Clinical Study"},{"pmid":"41642375","year":"2026","title":"Uncovering the molecular basis of high morphinan product efficiency in opium poppy through Multi-omics integrated analysis with multi-capsules.","finding":"","journal":"Plant molecular biology","studyType":"Clinical Study"},{"pmid":"41406916","year":"2026","title":"Metabolomic signatures predict heterotic performance in opium poppy (Papaver somniferum).","finding":"","journal":"Plant physiology and biochemistry : PPB","studyType":"Clinical Study"}],"tags":[{"label":"noscapine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Cytochrome P450 2C19","category":"target"},{"label":"CYP2C19","category":"gene"},{"label":"SLC22A2","category":"gene"},{"label":"CYP2C9","category":"gene"},{"label":"R05DA07","category":"atc"},{"label":"Active","category":"status"},{"label":"Antitussive Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Respiratory System Agents","category":"pharmacology"}],"phase":"discontinued","safety":{"safetySignals":[{"llr":541.339,"date":"","count":170,"signal":"Toxicity to various agents","source":"DrugCentral FAERS","actionTaken":"Reported 170 times (LLR=541)"},{"llr":238.817,"date":"","count":73,"signal":"Drug abuse","source":"DrugCentral FAERS","actionTaken":"Reported 73 times (LLR=239)"}],"commonSideEffects":[{"effect":"Toxicity to various agents","drugRate":"LLR 541","severity":"serious"},{"effect":"Drug abuse","drugRate":"LLR 239","severity":"common"}],"contraindications":["Acute hepatitis","Alcoholism","Angina pectoris","Chronic heart failure","Continuous fever","Cor pulmonale","Cystic fibrosis","Diabetes mellitus","Disease of liver","Hypertensive disorder","Hyperthyroidism","Hypothyroidism","Multiple organ failure","Myocardial infarction","Peptic ulcer","Pulmonary edema","Seizure disorder","Sepsis syndrome","Severe Hypoxemia","Shock","Smokes tobacco daily","Smoking cessation assistance","Tachyarrhythmia","Theophylline Toxicity","Third trimester pregnancy"]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"vadebex","offLabel":[],"synonyms":["noscapine","methoxyhydrastine","narcompren","narcosine","noscapalin","noscapin","terbenol","vadebex","noscapine hydrochloride","noscapine HCl"],"timeline":[],"aiSummary":"Vadebex, also known as noscapine, is a small molecule drug that targets the Cytochrome P450 2C19 enzyme. It is a noscapine drug class, but its commercial status and approved indications are unknown. The drug has a half-life of 2.13 hours and bioavailability of 30%. As a noscapine drug, its mechanism of action is not fully understood, but it is thought to work by inhibiting microtubule dynamics, which can lead to cell cycle arrest and apoptosis in cancer cells. Further research is needed to fully understand its effects and potential uses.","approvals":[],"brandName":"Vadebex","ecosystem":[],"mechanism":{"target":"Cytochrome P450 2C19, Cytochrome P450 2C9, Multidrug and toxin extrusion protein 1","targets":[{"gene":"CYP2C19","source":"DrugCentral","target":"Cytochrome P450 2C19","protein":"Cytochrome P450 2C19"},{"gene":"SLC22A2","source":"DrugCentral","target":"Solute carrier family 22 member 2","protein":"Solute carrier family 22 member 2"},{"gene":"CYP2C9","source":"DrugCentral","target":"Cytochrome P450 2C9","protein":"Cytochrome P450 2C9"},{"gene":"SLC47A1","source":"DrugCentral","target":"Multidrug and toxin extrusion protein 1","protein":"Multidrug and toxin extrusion protein 1"}],"modality":"Small Molecule","drugClass":"noscapine","explanation":"Imagine your cells are like a factory with many moving parts. Vadebex works by disrupting the tiny 'roads' that these parts move along, which can cause the factory to shut down and eventually die. This can be helpful in treating certain types of cancer.","oneSentence":"Vadebex works by inhibiting microtubule dynamics, which can lead to cell cycle arrest and apoptosis in cancer cells.","technicalDetail":"Vadebex exerts its effects by binding to the colchicine binding site on tubulin, a key component of microtubules, and inhibiting microtubule polymerization and dynamics, leading to cell cycle arrest and apoptosis in cancer cells."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1973","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=NOSCAPINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NOSCAPINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T13:03:06.356164","biosimilars":[],"competitors":[{"drugName":"hydrocodone","drugSlug":"hydrocodone","fdaApproval":"1943-03-23","patentExpiry":"Sep 13, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"codeine","drugSlug":"codeine","fdaApproval":"1952-01-21","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"morphine","drugSlug":"morphine","fdaApproval":"","patentExpiry":"Mar 12, 2034","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"dextromethorphan","drugSlug":"dextromethorphan","fdaApproval":"1957-12-03","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"noscapine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"hydrocodone","brandName":"hydrocodone","genericName":"hydrocodone","approvalYear":"1943","relationship":"same-class"},{"drugId":"codeine","brandName":"codeine","genericName":"codeine","approvalYear":"1952","relationship":"same-class"},{"drugId":"morphine","brandName":"morphine","genericName":"morphine","approvalYear":"","relationship":"same-class"},{"drugId":"dextromethorphan","brandName":"dextromethorphan","genericName":"dextromethorphan","approvalYear":"1957","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT00912899","phase":"PHASE1","title":"A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Cougar Biotechnology, Inc.","startDate":"2007-12","conditions":["Refractory Multiple Myeloma"],"enrollment":12,"completionDate":"2010-07"},{"nctId":"NCT00183950","phase":"PHASE1,PHASE2","title":"Study of Noscapine for Patients With Low Grade Non Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2000-03","conditions":["Non-Hodgkin's Lymphoma","Chronic Lymphocytic Leukemia"],"enrollment":12,"completionDate":"2006-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NUI":"N0000166975","NDDF":"001654","UNII":"8V32U4AOQU","CHEBI":"CHEBI:73237","INN_ID":"632","RXNORM":"7533","UMLSCUI":"C0028426","ChEMBL_ID":"CHEMBL364713","KEGG_DRUG":"D01036","DRUGBANK_ID":"DB06174","PDB_CHEM_ID":" 08N","PUBCHEM_CID":"275196","SNOMEDCT_US":"387437002","IUPHAR_LIGAND_ID":"10212","SECONDARY_CAS_RN":"912-60-7","MESH_DESCRIPTOR_UI":"D009665"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"2.13 hours","clearance":"16.88 mL/min/kg","bioavailability":"30%","volumeOfDistribution":"2.3 L/kg"},"publicationCount":587,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"R05DA07","allCodes":["R05DA07"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026","pmid":"41717434","title":"In silico evaluation of natural opioid ligands interaction and their therapeutic prospects in neuroinflammation.","journal":"In silico pharmacology"},{"date":"2026 Feb 13","pmid":"41686195","title":"Fabrication of Bortezomib and Noscapine-loaded PLGA nanoparticles: investigation of anti-bacterial, anti-proliferative activity, and apoptosis induction in triple-negative breast cancer cells.","journal":"Naunyn-Schmiedeberg's archives of pharmacology"},{"date":"2026 Feb 9","pmid":"41663458","title":"Phenotypic classification of opium poppy genotypes (Papaver somniferum L.) based on morpho-phenological traits.","journal":"Scientific reports"},{"date":"2026 Feb 5","pmid":"41642375","title":"Uncovering the molecular basis of high morphinan product efficiency in opium poppy through Multi-omics integrated analysis with multi-capsules.","journal":"Plant molecular biology"},{"date":"2026 Jan","pmid":"41406916","title":"Metabolomic signatures predict heterotic performance in opium poppy (Papaver somniferum).","journal":"Plant physiology and biochemistry : PPB"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}